We are live on ! Find out more
PTHS icon

Pelthos Therapeutics
PTHS

5 hedge funds and large institutions have $290K invested in Pelthos Therapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding

Funds holding: 1 → 5 (+4)

1.25% less ownership

Funds ownership: 5.06% → 3.81% (-1.2%)

63% less capital inflows, than outflows

Capital inflows: $31.8K | Capital outflows: $85.6K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
+4
Holders Change %
+400%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$31.5K
2
UBS Group
UBS Group
Switzerland
+$320
3
Bank of America
Bank of America
North Carolina
+$17
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$17

Top Sellers

Rank Fund Capital Flow
1
Anson Funds Management
Anson Funds Management
Texas
-$85.6K

PTHS Hedge Fund Activity: Q2 2024 in Review

5 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q2 2024, worth a combined $290K — down 56% from $660K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PTHS positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.5K. The largest seller was Anson Funds Management, cutting an estimated $85.6K.

  • 5 institutional investors held Pelthos Therapeutics (PTHS) as of Q2 2024, up from 1 in Q1 2024.
  • Funds reported $290K of Pelthos Therapeutics stock for Q2 2024, down 56% quarter-over-quarter.
  • 4 funds opened new Pelthos Therapeutics positions in Q2 2024 and 0 closed out, a net change of +4 holders.
  • The largest Pelthos Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $31.5K added.
  • The largest Pelthos Therapeutics seller in Q2 2024 was Anson Funds Management, an estimated $85.6K sold.

Based on aggregated 13F filings for Q2 2024.